Johnson & Johnson (JNJ) Tops Q3 EPS by 24c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Johnson & Johnson (JNJ) Reports a Beat-and-Raise 3Q, Analyst Positive
October 19, 2021 7:53 AM EDTJohnson & Johnson (NYSE: JNJ) reported better-than-expected 3Q results today and left its vaccine guidance unchanged.
The company reported Q3 EPS of $2.60 to top the analyst estimate of $2.36. However, revenue for the quarter came in at $23.3 billion to miss the consensus estimate of $23.74 billion. The company left its COVID-19 vaccine sales target unchanged at $2.5... More
